LONG-TERM EFFECTIVENESS AND SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Introduction: Erythropoiesis-stimulating agents (ESA) are the primary treatment for anemia in most patients with low to moderate-risk myelodysplastic syndromes. However, in some patients, ESA therapy is not effective, and emerging evidence suggests that Luspatercept may offer longstanding benefits i...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2024-10-01
|
| Col·lecció: | Hematology, Transfusion and Cell Therapy |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S253113792401085X |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|